Beam Therapeutics (BEAM) Current Deferred Revenue (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Current Deferred Revenue data on file, last reported at $304000.0 in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $304000.0, down 99.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $304000.0 (down 99.64% YoY), and the FY2025 annual result was $6.7 million, down 95.31% from the prior year.
• Current Deferred Revenue declined to $304000.0 in Q1 2026 per BEAM's latest filing, from $6.7 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $338.2 million in Q4 2022 and troughed at $304000.0 in Q1 2026.
• A 5-year average of $121.4 million and a median of $115.0 million in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2026: Current Deferred Revenue surged 1147.09% in 2022, then tumbled 99.64% in 2026.
• A 5-year view of Current Deferred Revenue shows it stood at $338.2 million in 2022, then tumbled by 47.19% to $178.6 million in 2023, then dropped by 20.45% to $142.1 million in 2024, then slumped by 95.31% to $6.7 million in 2025, then slumped by 95.43% to $304000.0 in 2026.
• Business Quant data shows BEAM's Current Deferred Revenue at $304000.0 in Q1 2026, $6.7 million in Q4 2025, and $110.3 million in Q3 2025.